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Summary
Background and aims: Inflammation is part of the
pathophysiology of congestive heart failure (CHF).
However, little is known about the impact of the
presence of systemic inflammatory disease (SID),
defined as inflammatory syndrome with constitu-
tional symptoms and involvement of at least two
organs as co-morbidity on the clinical course and
prognosis of patients with CHF.
Methods and results: This is an analysis of all 622
patients included in TIME-CHF. After an 18 months
follow-up, outcomes of patients with and without
SID were compared. Primary endpoint was all-
cause hospitalization free survival. Secondary end-
points were overall survival and CHF hospitalization
free survival. At baseline, 38 patients had history of
SID (6.1%). These patients had higher N-terminal
pro brain natriuretic peptide and worse renal
function than patients without SID. SID was a risk
factor for adverse outcome [primary endpoint:
hazard ratio (HR) = 1.73 (95% confidence interval:
1.18–2.55, P=0.005); survival: HR=2.60 (1.49–
4.55, P=0.001); CHF hospitalization free survival:
HR=2.3 (1.45–3.65, P<0.001)]. In multivariate
models, SID remained the strongest independent
risk factor for survival and CHF hospitalization free
survival.
Conclusions: In elderly patients with CHF, SID is
independently accompanied with adverse outcome.
Given the increasing prevalence of SID in the
elderly population, these findings are clinically
important for both risk stratification and patient
management.
Introduction
Despite substantial progress in the management
of congestive heart failure (CHF), morbidity and
mortality remain unacceptably high.1–3 In addition
to progression of CHF, non-cardiac co-morbidities
may negatively impact the course of disease.
Identification of such CHF modifying co-morbidities
is not only crucial for risk stratification but it may
also influence treatment of individual patients.
Since the early 1990s when Levine et al.4 reported
on elevated levels of an inflammatory cytokine—i.e.
tumour necrosis factor (TNF)—in patients with CHF,
the link between CHF and inflammation is estab-
lished. Meanwhile, a number of studies have
demonstrated that inflammation may contribute to
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the pathophysiology and disease progression in
CHF and that inflammatory biomarkers correlate
with disease severity and outcome.5,6
However, little is known about the impact of non-
cardiac co-morbidities that are associated with
chronic inflammation on disease progression and
prognosis in CHF. Since systemic inflammation is
the key factor, systemic inflammatory diseases
(SIDs) may be particularly relevant in this regard.
SID can be defined as inflammatory syndromes
with constitutional or general symptoms and
involvement of different organ systems. They
include vasculitic and connective tissue diseases
such as giant cell arteritis (GCA), polymyalgia
rheumatica (PMR), rheumatoid arthritis (RA) and
systemic lupus erythematosus (SLE).7,8 Because of
their high prevalence in the elderly, RA, PMR and
GCA are of special clinical importance in popula-
tions with chronic diseases such as CHF.9,10
To determine the impact of SID on the clinical
course and prognosis of CHF in elderly patients,
we performed a post hoc analysis of the prospective
randomized controlled multicentre trial of intensi-
fied vs. standard medical therapy in elderly patients
with CHF (TIME-CHF). This trial was designed to
compare 18 months outcomes of N-terminal pro
brain natriuretic peptide (NT-proBNP)-guided vs.
symptom-guided therapy in patients aged 60 years
or older with symptomatic CHF.11
Methods
TIME-CHF study
The detailed study design and methods of the multi-
centre TIME-CHF study11 and the principal findings
of pts with depressed LV function have been
reported in detail previously.12 In brief, patients
aged 560 years with dyspnoea New York Heart
Association function class (NYHA) 5II on current
therapy, a history of hospitalization for CHF within
the last year and elevated NT-proBNP levels were
included. Excluded were patients as previously
defined.11 Overall, 622 patients were included and
stratified by age and left ventricular ejection fraction
(LVEF). Patients were randomized into two treatment
strategies, i.e. symptom-guided or intensified
NT-proBNP-guided therapy. Medical therapy was
prescribed according to current guidelines with pre-
defined escalating rules to reduce either symptoms
or NT-proBNP levels to predefined target values.
Patients were followed up in the outpatient clinics
of each centre with prespecified visits after 1, 3, 6,
12 and 18 months.
At inclusion, patient history was taken. SID was
defined as the diagnosis of one of the following
diseases: PMR, GCA, RA/polyarthritis, SLE,
Sjoegren’s syndrom (SS), dermatomyositis, polymyo-
sitis (PM), systemic sclerosis, remitting seronegative
symmetrical synovitis with pitting oedema (RS3PE)
and spondylitis ankylosing (SA). Presence of SID was
reported by local investigator and for this analysis
verified centrally by a second review of individual
hospital charts. Charlson score was used as a marker
of global morbidity as previously described. In brief
more than 5 indicate a very high co-morbidity class,
whereas 3–4, 1–2 or 0 points indicate high, medium
or low co-morbidity classes, respectively.13
The primary endpoint of TIME-CHF was all-cause
hospitalization free survival. Secondary endpoints
were survival and heart failure hospitalization free
survival. Per protocol, cancer-related death and hos-
pitalizations were not considered as endpoints.
Statistical analysis
Results are presented as frequencies, mean (SD) or
median (interquartile range), as appropriate.
Between-group comparisons were performed using
Student’s t-test, Mann–Whitney U-test or Pearson
chi-square-test, as appropriate. Kaplan–Meier
curves were used for calculating time-dependent oc-
currences of events. For comparison between
groups, the log-rank test was used. Hazard ratio
(HR) was derived from univariable Cox regression
and tested for independence using multivariable
Cox regression entering gender, age, body mass
index, LVEF, coronary artery disease (CAD), cardio-
vascular risk factors, other co-morbidities, symptoms
and clinical signs of CHF, blood pressure (BP), heart
rate, creatinine, NT-proBNP, QRS width, medica-
tion including non-steroidal antirheumatic drugs
(NSAID) and corticosteroids as co-variables.
A two-sided P-value of 0.05 was considered to
be statistically significant. All calculations were
performed with the use of the SPSS statistical pack-
age version 15.0 (SPSS Inc, Chicago, IL, USA).
Results
Thirty-eight of the 622 patients (6.1%) were classi-
fied as having SID at baseline. Baseline characteris-
tics of patients with and without SID are shown in
Table 1. Patients with SID suffered significantly
more from inflammatory bowel disease and osteo-
porosis, had higher NT-proBNP and serum creatin-
ine values. Their baseline medication included more
often NSAIDs and corticosteroids. There was no
difference, however, in heart failure medication
between the two groups. As shown in Table 2,
most patients had PMR, GCA or RA as the SID-
defining diagnosis.
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During the 18-month follow-up, patients with
SID exhibited a significantly worse outcome than
patients without SID. Thus, all-cause hospitalization
free survival was 26.3% vs. 40.6% [P=0.006,
Figure 1a; HR=1.73 (95% confidence interval (CI)
1.18–2.55), P=0.005], overall 18-month survival
63.2% vs. 81.5% [P=0.001, Figure 1b; HR=2.60
(95% CI 1.49–4.55), P=0.001] and survival free
of heart failure hospitalization 47.5% vs. 67.5%
[P<0.001, Figure 1c; HR=2.30 (95% CI 1.45–
3.65), P<0.001]. In multivariable analysis, the pres-
ence of SID was the strongest independent predictor
for survival and survival free of heart failure
Table 1 Baseline characteristics
No SID
n=584
SID
n=38
P-value
Age (years) 76.9 7.6 76.5 6.7 0.69
Female (%) 232 (39.7) 21 (55.3) 0.059
NT-proBNP-guided therapy (%) 289 (49.5) 21 (55.3) 0.49
Systolic dysfunction (%) 469 (80.3) 30 (78.9) 0.838
Body mass index 25.7 4.4 25.1 4.7 0.477
LVEF% 35 13 34 14 0.464
NT-proBNP (pg/ml) 3736 (1903–6837) 4940 (2689–8143) 0.048
Creatinine (mg/dl) 115 38 128 40 0.05
CRP (mg/l) 9.0 (0–14) 9.5 (1–32) 0.206
Heart rate (beats/min) 75 14 78 14 0.30
Systolic BP (mmHg) 122 20 123 22 0.744
Primary cause of heart failure (%)
CAD 312 (53.4) 18 (47.4) 0.808
Dilated cardiomyopathy 84 (14.4) 5 (13.2)
Valvular heart disease 21 (3.6) 2 (5.3)
Hypertensive heart disease 160 (27.4) 13 (34.2)
Other 7 (1.2) 0
Co-morbidities (%)
Previous myocardial infarction 272 (46.6) 14 (36.8) 0.243
Hypertension 433 (74.1) 29 (76.3) 0.767
Diabetes mellitus 209 (35.8) 13 (34.2) 0.844
Insulin dependent DM 81 (13.9) 2 (5.3) 0.131
Stroke/transient ischaemic attack 92 (15.8) 6 (15.8) 0.995
COPD 118 (20.2) 6 (15.8) 0.509
Kidney disease 331 (56.7) 24 (63.2) 0.434
Cancer 84 (14.4) 2 (5.3) 0.115
Inflammatory bowel disease 8 (1.8) 3 (7.9) 0.003
Osteoporosis 60 (10.3) 10 (26.3) 0.002
Charlson score 3 (2–4) 3 (2–5) 0.35
Medication (%)
NSAID 110 (18.8) 13 (34.2) 0.021
NSAID on demand 33 (5.7) 3 (7.9) 0.566
Corticosteroids 81 (13.9) 20 (52.6) <0.001
ACE-inhibitor or ARB 541 (92.6) 38 (100) 0.083
b-Blocker 449 (76.9) 27 (71.1) 0.411
Spironolactone 217 (37.2) 17 (44.7) 0.354
Loop diuretics 540 (92.5) 35 (92.1) 0.935
Data are given as counts and percentages, mean SD or median (interquartile range) as appropriate. DM, diabetes mellitus;
COPD, chronic obstructive pulmonary disease; ARB, angiotensin receptor blocker.
Table 2 Different SIDs at baseline
SID n=38
PMR/GCA 18
RA/polyarthritis 7
SA 2
SS 1
SLE 1
RS3PE 1
PM 1
Not specified 7
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hospitalization, whereas the presence of SID was
no longer an independent predictor for all-cause
hospitalization free survival (Table 3). Other strong
independent predictors for overall survival or survival
free of heart failure hospitalization were CAD as
main cause of CHF, and history of cancer or syncope.
Regarding all-cause hospitalization free survival,
the strongest predictors for poor outcome were
preserved LVEF and CAD as main cause of CHF.
Analysis of anti-inflammatory drug use revealed
that utilization of corticosteroids was an independ-
ent predictor for a worse outcome in regard to all-
cause hospitalization free survival (HR 1.45, 95% CI
1.1–1.92, P=0.008), whereas NSAID use was an
independent predictor for better survival (HR 0.42,
95% CI 0.24–0.74, P=0.002) and better survival
free of heart failure hospitalization (HR 0.68, 95%
CI 0.45–0.99, P=0.049).
Figure 1. (a) Kaplan Meier analysis for the primary end-
point all-cause hospitalization free survival. (b) Kaplan
Meier analysis for the secondary endpoints overall sur-
vival and (c) CHF hospitalization free survival.
Table 3 Predictors for adverse outcome and HRs in
multivariate analysis for the different endpoints
HR 95% CI P-value
Hospital-free survival
SID 1.32 0.87–2.0 0.2
Preserved LVEF 1.586 1.213–2.073 0.001
Primary cause CAD 1.496 1.174–1.907 0.001
Charlson score 1.146 1.070–1.227 <0.001
Prednison use 1.453 1.102–1.916 0.008
Angina pectoris at baseline 1.453 1.129–1.87 0.004
Anaemia at baseline 1.311 1.045–1.644 0.019
Elevated JVP 1.177 1.070–1.296 0.001
Serum-creatinine 1.003 1.000–1.006 0.037
QRS width 1.003 1.001–1.006 0.022
Overall survival
SID 2.951 1.651–5.275 <0.001
Serum NT-proBNP log 10 2.275 1.359–3.810 0.002
Primary cause CAD 2.136 1.394–3.271 <0.001
Anaemia at baseline 2.161 1.479–3.159 <0.001
History of syncope 2.158 1.163–4.003 0.015
Cancer 2.104 1.364–3.245 0.001
Rales on auscultation 1.548 1.225–1.957 <0.001
NYHA class at baseline 1.397 1.001–1.951 0.05
Charlson score 1.188 1.069–1.319 0.001
QRS width 1.009 1.004–1.013 <0.001
NSAID use 0.424 0.244–0.739 0.002
CHF-hospital-free survival
SID 2.708 1.675–4.377 <0.001
Cancer 2.332 1.622–3.353 <0.001
Osteoporosis 2.127 1.401–3.229 <0.001
Primary cause CAD 1.955 1.438–2.658 <0.001
History of syncope 1.904 1.208–3.001 0.006
Anaemia at baseline 1.807 1.351–2.415 <0.001
Rales on auscultation 1.653 1.398–1.955 <0.001
Diabetes mellitus 1.641 1.213–2.220 0.001
Serum creatinine 1.008 1.005–1.012 <0.001
QRS width 1.007 1.003–1.011 <0.001
NSAID use 0.675 0.456–0.998 0.049
JVP, jugular venous pressure.
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Baseline characteristics of pts with NSAID use
are shown in Table 4. Pts receiving NSAID as
co-medication were more often female and had
lower NT-proBNP and serum creatinine values.
There were no differences in terms of age or LVEF
between NSAID-users and non-users.
Discussion
To the best of our knowledge, this subgroup analysis
of the TIME-CHF study is the first to show that the
presence of a SID is strongly associated with poor
outcome in elderly patients with CHF. The negative
impact of SID could be demonstrated in all analysed
endpoints—not only regarding mortality and all
cause hospitalization rates but also the more disease
specific endpoint of CHF hospitalization free
survival. In multivariable analysis including other
well established prognostic markers, the presence
of SID remained the strongest independent negative
predictor for overall survival and survival free of
heart failure hospitalization. Given the increasing
prevalence of SID in the elderly population, which
is also prone to CHF, these findings are clinically
important for both risk stratification and patient
management.
It is not uncommon that clinicians have to provide
health care for patients with SID and CHF. Most
relevant epidemiological data about SID focus on
specific subgroups and disease entities, respectively.
They are derived from unselected patient popula-
tions with possibly important ethnic and geographic
variations. Nevertheless, it was estimated that
almost 22% of all Americans had some form of
arthritis or rheumatic condition in 2003–05 with a
projected increase in the prevalence up to 40% by
2030.9,10 With respect to vasculitic diseases, there
is a broad difference in incidence and prevalence
according to the specific disease.14 The most fre-
quently encountered disease entities in our study
cohort were PMR/GCA and RA. The prevalence of
PMR/GCA is estimated to be 7.4/1000 and 2.8/1000
persons, respectively, over 50 years of age with a
dramatical increase with increasing age. In patients
aged 75–79 years, the prevalence is 19.8/1000 and
6.2/1000, respectively, whereas in patients aged
90 years or older, it rises to 40.7/1000 and 17.2/
1000, respectively.9 For RA, available data suggests
that the overall prevalence among adults older than
34 years is 8.5/1000 persons with an increase with
increasing age and a peak prevalence in patients
aged 65–74 years (male 16/1000, female 24/
1000).10 In our cohort, the cumulative prevalence
of SID was 6%, highlighting the frequency of this
co-morbidity in elderly CHF patients.
The fact that the presence of SID was the strongest
independent negative predictor for survival free of
CHF hospitalization and survival but did not predict
independently all-cause hospitalization free survival
might suggest a disease modifying role of SID in
CHF. An inherent feature of SID is the presence of
immune activation with elevation of inflammatory
cytokines. Among others, elevation of IL-6 and
TNF-a is characteristic in SID and may serve as a
marker for disease activity.15–18 Immune activation
with elevation of IL-6 and TNF-a is also one of
the key mechanisms implicated in the propagation
of myocardial failure. Levels of IL-6 and TNF-a
correlate with both severity of CHF and the devel-
opment of new-onset CHF, thus implicating a patho-
physiological role of these mediators in CHF.19,20
Mechanistically, IL-6 and TNF-a were shown to
impair myocardial contractile function thereby
propagating the development of CHF.21,22 IL-6 was
also found to correlate with LV systolic and diastolic
dysfunction in the general population and in
patients with RA.23 Given a pathophysiological
role of these inflammatory cytokines in CHF, it is
tempting to speculate that an enhanced systemic
inflammation triggered by SID may directly influ-
ence the course of co-existing CHF. A direct associ-
ation remains, however, unproven and would have
to be tested in a prospective intervention trial.
Moreover, inhibition of TNF-a in CHF patients not
selected based on inflammation did not improve
outcome.24
Table 4 Baseline characteristics of patients with NSAID use
Characteristic No NSAID use
n=499
NSAID use
n=123
P-value
Age (years) 76.9 7.5 77.1 7.8 0.08
Female (%) 191 (38.3) 62 (50.4) 0.014
NT-proBNP (pg/ml) 4007 (2020–7194) 3197 (1741–5876) 0.016
Creatinine (mg/dl) 117 39 110 34 0.028
LVEF (%) 35 13 36 13.4 0.214
Data are given as counts and percentages, mean SD or median (interquartile range) as appropriate.
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The use of concomitant medication may nega-
tively influence prognosis. Often, patients with
SID are treated with steroids and NSAIDs. In CHF
patients, the association between NSAID intake and
worsening symptoms is well established. Particularly
in elderly CHF patients, the use of NSAIDs has
been associated with an up to 10-fold increased
risk of worsening CHF requiring hospitalization.25
In our cohort, however, the NSAID use was asso-
ciated with a better overall survival and survival
without CHF hospitalization. This finding should
be interpreted with great caution because it may
be biased by the possibility that healthier patients
received NSAIDs, whereas in sicker patients
NSAIDs were withhold—as suggested by the differ-
ences in baseline characteristics of those receiving
NSAIDs compared to those not receiving NSAIDs.
Moreover, NSAIDs were not randomly assigned.
Though provocative, our results nevertheless suggest
that a prospective study of NSAID use in CHF
patients and significant systemic inflammation
might be worthwhile considering.
Likewise corticosteroid use may be associated
with a worse cardiovascular outcome. Use of thera-
peutic doses of glucocorticoids are associated with
higher rates of myocardial infarction, stroke, CHF
and all-cause mortality as shown in large population
based studies.26,27 Chronic glucocorticoid intake
may lead to fluid retention, hypertension, dyslipide-
mia and hyperglycaemia and thereby may worsen
heart failure symptoms and accelerate atheroscler-
osis.28–30 In patients with SID, however, the cardio-
vascular effects of chronic corticosteroid therapy
remain to be determined. In RA patients, there are
conflicting data whether corticosteroids have a more
favourable effect on cardiovascular outcome by
reducing inflammation or an unfavourable effect
due to their above-mentioned cardiovascular and
metabolic side effects.31–34 In our cohort, use of
corticosteroids was negatively associated with the
combined endpoint of all-cause hospitalization
and mortality. Again, these results should be inter-
preted with caution, due to the presence of potential
confounding factors, the limited number of patients
receiving chronic corticosteroids in our cohort and
the lack of prospective randomized assignment of
corticosteroid use.
Intriguingly, we observed that heart failure with
preserved ejection fraction (HFpEF) was a strong
negative predictor of the primary endpoint all
cause hospitalization free survival but not the
other endpoints. This observation in the TIME-CHF
was recently discussed by Maeder et al.35 One
possible reason for this observation was that the def-
inition of HFpEF was tighter than in other prospect-
ive trials on HFpEF. Thus, the NT-proBNP cut-off
applied in our study was higher than proposed in
the most recent recommendations for the diagnosis
of HFpEF and the median NT-proBNP of for, e.g. in
the PEP-CHF and I-PRESERVED trials. Therefore, we
selected a population of patients in whom confi-
dence of HFpEF diagnosis was high, and the patients
were sicker than in other HFpEF trials.35
Our study has several limitations. It is a post hoc
analysis of a prospective trial with a limited number
of patients suffering from SID. The presence of
co-morbidities including SID was reported by inves-
tigators, based on the personal and documented
case history. There was no complete documentation
of date of first diagnosis, duration of the SID, disease
activity and previous treatment. In addition, there
was no information about the extent of inflammation
at study entry. A significant part of patients was
included directly after a CHF related hospitalization
and some of them had suffered from concomitant
infection. Therefore, C-reactive protein (CRP) levels
at inclusion do not necessarily reflect the extent
of inflammatory activation triggered by SID. As
mentioned, a causative relation between medication
and outcome cannot be proven by this retrospective
analysis and is hypothesis generating only.
Conclusion
SIDs, in particular PMR/GCA and RA, are common
in an elderly CHF population and associated with
a poor outcome, which requires special attention.
Whether SID has a direct causal influence on prog-
nosis and whether specific treatment of SID may
improve outcome in CHF remains to be determined.
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